2015 Therapeutic Proteins

Strategies and themes for currently approved MABs and Fusion Proteins

  1. the same target may be active in different diseases, therefore the same drug (or a different drug targeting the same protein or process) may be used to treat different diseases
    • e.g.
      • VEGF in colon cancer and macular degeneration
      • CTLA4 in psoraisis and rheumatoid arthritis

  2. different antibodies (humanized vs. chimeric) may be used against the same target (usually because different drug companies use different approaches to design the drugs)
    • e.g. basiliximab and daclizumab target the interleukin 2 receptor (CD25) and are used in organ transplantation

  3. cytotoxic agents can be used to increase efficacy
    • e.g., ibritumomab and tositumomab vs. rituximab and oftatumomab in cancer treatment
Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 27-apr-15 1:11 PM